APA

Piccardo A., Puntoni M., Morbelli S., Massollo M., Bongioanni F., Paparo F., Altrinetti V., Gonella R., Gennari A., Iacozzi M., Sambuceti G. & DeCensi A. (20160502). 18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT. : Nuklearmedizin. Nuclear medicine.

Chicago

Piccardo A, Puntoni M, Morbelli S, Massollo M, Bongioanni F, Paparo F, Altrinetti V, Gonella R, Gennari A, Iacozzi M, Sambuceti G and DeCensi A. 20160502. 18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT. : Nuklearmedizin. Nuclear medicine.

Harvard

Piccardo A., Puntoni M., Morbelli S., Massollo M., Bongioanni F., Paparo F., Altrinetti V., Gonella R., Gennari A., Iacozzi M., Sambuceti G. and DeCensi A. (20160502). 18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT. : Nuklearmedizin. Nuclear medicine.

MLA

Piccardo A, Puntoni M, Morbelli S, Massollo M, Bongioanni F, Paparo F, Altrinetti V, Gonella R, Gennari A, Iacozzi M, Sambuceti G and DeCensi A. 18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT. : Nuklearmedizin. Nuclear medicine. 20160502.